Researchers link GLP1 agonists to depression risk in some users and call for personalized prescribing based on genetic ...

Eli Lilly and Company has announced positive topline Phase 3 results from Achieve-1, evaluating the safety and efficacy of ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

Semaglutide promising alternative treatment for chronic myopathy of hyperkalemic periodic paralysis suggests a case report ...

胰高血糖素样肽-1受体GLP1R激动剂，如司美格鲁肽，因其在治疗肥胖和糖尿病方面的显著疗效而在被广泛使用。然而，一项最新的研究通过计算机模拟药理基因组学评估，对GLP1R激动剂与遗传性成瘾风险评分（GARS）相关通路进行了深入分析，结果显示这些减肥药 ...

Yogurt may get more attention, but this protein-packed dairy product can play a role in wellness and weight loss, too.